Revista de la Asociación Argentina de Ortopedia y Traumatología · Oct 27, 2026
Preoperative use of GLP-1 receptor agonists and postoperative outcomes in patients undergoing arthroplasty: systematic review with exploratory meta-analysis
By Jurado HAR, Jurado EAR
INTRODUCTION: Arthroplasty is a common procedure in older adults with multiple comorbidities. Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes mellitus and obesity. Their administration before surgery could influence postoperative outcomes in patients undergoing different arthroplasties, although the available evidence is inconsistent. OBJECTIVE: To evaluate the association between preoperative use of GLP-1 agonists and postoperative complications in patients undergoing arthroplasty. MATERIALS AND METHODS: A systematic review was conducted following the PRISMA 2020 guideline, with support from artificial intelligence to optimize the search in PubMed, Scopus, and Web of Science. Studies of patients undergoing hip, knee, or shoulder arthroplasty who had received GLP-1 agonists and had postoperative complications and a hospital readmission within 90 days were included. An exploratory analysis was performed using odds ratio (OR), 95% CI, p value, and I² with a random-effects model. RESULTS: Four observational studies were analyzed. Preoperative administration of GLP-1 agonists was associated with a lower OR of surgical site infection (OR 0.48; 95% CI 0.35-0.66; p <0.001; I² = 0%). Hospital readmission showed high heterogeneity (I² = 86%). CONCLUSIONS: Preoperative use of GLP-1 agonists was associated with a lower OR of postoperative infection in patients undergoing arthroplasty. However, the small number of observational studies and the heterogeneity across arthroplasties require the findings to be interpreted with caution and considered hypothesis-generating.
doi.org/10.15417/issn.1852-7434.2026.91.5.2326Open accessInterventions